Leerink Partners Reiterates a Buy Rating on Geron Corporation (GERN)

Geron Corporation (NASDAQ:GERN) is one of the 13 Stocks Under $5 With High Upside Potential. In a report released on June 1, Faisal Khurshid from Leerink Partners reiterated a Buy rating on Geron Corporation (NASDAQ:GERN).

Is Geron Corp. (GERN) the Best Nasdaq Stock Under $5 to Buy?

A close-up of a laboratory technician in a laboratory, measuring a newly developed biopharmaceutical drug.

The company reported $39.4 million in net product revenue for RYTELO (imetelstat) in Q1 2025, continuing the first year of US commercialization. Demand for RYTELO in the 13-week period through the week ending March 28 rose 1% compared to the prior 13 weeks.

Geron Corporation (NASDAQ:GERN) also attained market authorization for the product as a monotherapy from the European Commission (EC), with launch planning underway. The company expects to commercialize RYTELO in select EU countries from 2026.

Geron Corporation (NASDAQ:GERN) is a biotechnology company that develops Imetelstat, a telomerase inhibitor in hematologic myeloid malignancies. It focuses on oncology-focused therapeutic products.

While we acknowledge the potential of GERN as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money.

Disclosure: None.